1. Overview of PAX3-FOXO1

• Genes involved:
  • PAX3 (Paired Box 3) – chromosome 2q35
  • FOXO1 (Forkhead Box O1) – chromosome 13q14
• Fusion: t(2;13)(q35;q14) → PAX3-FOXO1 fusion gene
• Result: Fusion protein acts as abnormal transcription factor, driving tumorigenesis

2. Tumor Association

• Primary tumor: Alveolar Rhabdomyosarcoma (ARMS)
  • Aggressive soft tissue sarcoma in children and adolescents
• Diagnostic Marker:
  • Detection of PAX3-FOXO1 via FISH, RT-PCR, or NGS confirms ARMS
• Other fusions:
  • PAX7-FOXO1 – usually associated with slightly better prognosis

3. Mechanism of Oncogenesis

• Fusion protein functions:
  • Acts as transcriptional activator/repressor
  • Alters expression of genes controlling cell proliferation, differentiation, and survival
• Key downstream targets:
  • MYCN, IGF2, MET, FGFR4 – promotes proliferation, survival, metastasis
• Effect: Blocks myogenic differentiation → aggressive tumor growth

4. Clinical Implications

• Prognosis:
  • PAX3-FOXO1 positive ARMS → worse prognosis than PAX7-FOXO1 or fusion-negative RMS
  • Higher risk of metastasis at diagnosis
• Treatment:
  • Multi-agent chemotherapy: Vincristine, Actinomycin D, Cyclophosphamide (VAC regimen) ± Ifosfamide/Etoposide (VAI/IE)
  • Surgery ± radiation for local control
  • Investigational targeted therapies (IGF1R inhibitors, FGFR inhibitors)

5. Key Notes for Clinical Reference

• Fusion type is critical prognostic biomarker in pediatric RMS
• PAX3-FOXO1 drives aggressive biology, guiding intensive therapy
• Molecular detection helps diagnosis, risk stratification, and clinical trial eligibility